One CRISPR treatment cut “bad” cholesterol in half for a full year

A single CRISPR infusion lowered LDL cholesterol by roughly half for a full year, with reports citing a 52.5% drop and a 53% reduction in levels. The data, released on September 27, 2026, describe the first sustained impact of gene editing on lipid profiles. The timing coincides with the trial’s initial dosing phase, putting the result in the spotlight within weeks of the first participant receiving the treatment.

ScienceDaily and Futura‑Sciences highlighted the trial’s design, noting that a one‑time CRISPR infusion achieved the lipid cut. Martin Cid Magazine echoed the 53% LDL decline, while Yahoo Health explained the gene‑editing mechanism targeting PCSK9. Health and Me speculated that the approach could eventually replace statins, though no comparative data were presented. OHSU News reported the enrollment of the first West Coast participant, suggesting expansion beyond the initial site. The coverage varies in emphasis, from mechanistic detail to therapeutic potential.

The articles omit any safety data beyond the twelve‑month follow‑up and do not outline regulatory milestones. Information on broader patient cohorts, dosing strategies, or head‑to‑head outcomes with statins is absent, leaving the durability of the cholesterol reduction and the pathway to clinical adoption uncertain.